Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LuLym-T
- Development stage
- Phase 2
- Lead developer
- Lukas Biomedical
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
LuLym-T is an autologous activated T lymphocyte (ATL) therapy developed by Lukas Biomedical. The treatment involves the ex vivo expansion and activation of a patient's own T cells, typically using anti-CD3 antibodies and interleukin-2 (IL-2), to enhance their cytotoxic potential against tumor cells. LuLym-T is primarily being investigated as an adjuvant immunotherapy to prevent recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative treatments such as surgical resection or radiofrequency ablation. By re-infusing a large population of activated effector cells, the therapy aims to eliminate minimal residual disease and improve long-term survival outcomes.
- Brand names
- LuLym-T
- Other names
- Activated T LymphocytesATLautologous activated T lymphocytes
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on LuLym-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LuLym-T.